Herrstedt J - Search Results

1

Casopitant: a novel NK(1)-receptor antagonist in the prevention of chemotherapy-induced nausea and vomiting.

Ruhlmann C, Herrstedt J. Ruhlmann C, et al. Among authors: herrstedt j. Ther Clin Risk Manag. 2009 Apr;5(2):375-84. doi: 10.2147/tcrm.s4026. Epub 2009 May 20. Ther Clin Risk Manag. 2009. PMID: 19536319 Free PMC article.

2

Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting.

Herrstedt J. Herrstedt J. Expert Opin Drug Saf. 2004 May;3(3):231-48. doi: 10.1517/eods.3.3.231.31076. Expert Opin Drug Saf. 2004. PMID: 15155151 Review.

3

Prevention of chemotherapy-induced nausea and vomiting in elderly cancer patients.

Jakobsen JN, Herrstedt J. Jakobsen JN, et al. Among authors: herrstedt j. Crit Rev Oncol Hematol. 2009 Sep;71(3):214-21. doi: 10.1016/j.critrevonc.2008.12.006. Epub 2009 Jan 22. Crit Rev Oncol Hematol. 2009. PMID: 19162507 Review.

4

Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy.

Herrstedt J, Apornwirat W, Shaharyar A, Aziz Z, Roila F, Van Belle S, Russo MW, Levin J, Ranganathan S, Guckert M, Grunberg SM. Herrstedt J, et al. J Clin Oncol. 2009 Nov 10;27(32):5363-9. doi: 10.1200/JCO.2009.21.8511. Epub 2009 Oct 5. J Clin Oncol. 2009. PMID: 19805683 Clinical Trial.

5

Palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomiting.

Ruhlmann C, Herrstedt J. Ruhlmann C, et al. Among authors: herrstedt j. Expert Rev Anticancer Ther. 2010 Feb;10(2):137-48. doi: 10.1586/era.09.175. Expert Rev Anticancer Ther. 2010. PMID: 20131990 Review.

6

Safety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting.

Ruhlmann CH, Herrstedt J. Ruhlmann CH, et al. Among authors: herrstedt j. Expert Opin Drug Saf. 2011 May;10(3):449-62. doi: 10.1517/14740338.2011.563235. Epub 2011 Mar 21. Expert Opin Drug Saf. 2011. PMID: 21417835 Review.

7

Fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting.

Ruhlmann CH, Herrstedt J. Ruhlmann CH, et al. Among authors: herrstedt j. Expert Rev Anticancer Ther. 2012 Feb;12(2):139-50. doi: 10.1586/era.11.199. Expert Rev Anticancer Ther. 2012. PMID: 22316362 Review.

8

Palonosetron and prednisolone for the prevention of nausea and emesis during fractionated radiotherapy and 5 cycles of concomitant weekly cisplatin-a phase II study.

Ruhlmann CH, Belli C, Dahl T, Herrstedt J. Ruhlmann CH, et al. Among authors: herrstedt j. Support Care Cancer. 2013 Dec;21(12):3425-31. doi: 10.1007/s00520-013-1926-0. Epub 2013 Aug 15. Support Care Cancer. 2013. PMID: 23949739 Clinical Trial.

9

Multinational study exploring patients' perceptions of side-effects induced by chemo-radiotherapy.

Ruhlmann CH, Iversen TZ, Okera M, Muhic A, Kristensen G, Feyer P, Hansen O, Herrstedt J. Ruhlmann CH, et al. Among authors: herrstedt j. Radiother Oncol. 2015 Nov;117(2):333-7. doi: 10.1016/j.radonc.2015.09.014. Epub 2015 Sep 11. Radiother Oncol. 2015. PMID: 26372344

10

Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial.

Ruhlmann CH, Christensen TB, Dohn LH, Paludan M, Rønnengart E, Halekoh U, Hilpert F, Feyer P, Kristensen G, Hansen O, Keefe D, Herrstedt J. Ruhlmann CH, et al. Among authors: herrstedt j. Lancet Oncol. 2016 Apr;17(4):509-518. doi: 10.1016/S1470-2045(15)00615-4. Epub 2016 Mar 4. Lancet Oncol. 2016. PMID: 26952945 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

197 results

Search Page

Filters